BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:retatrutide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of retatrutide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06662383-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:retatrutide: Phase 3 readout est. (NCT06662383)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesit
 y\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06662383
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982859-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:retatrutide: Phase 1 readout est. (NCT06982859)
DESCRIPTION:retatrutide\, phase 1\, Type 2 Diabetes.\nStudy: A Study to Eva
 luate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivi
 ty in Adult Participants With Type 2 Diabetes Mellitus\nEstimated primary 
 completion: January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/retatrutide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06982859
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467447-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:retatrutide: Phase 2 readout est. (NCT07467447)
DESCRIPTION:retatrutide\, phase 2\, Obesity.\nStudy: Effect of Retatrutide 
 Versus Placebo in Participants Who Have Obesity or Are Overweight\nEstimat
 ed primary completion: 14 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07467447
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232719-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:retatrutide: Phase 3 readout est. (NCT07232719)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants With Obesity or Overweight\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/retatrutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232719
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035093-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:retatrutide: Phase 3 readout est. (NCT07035093)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Lo
 w Back Pain\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07035093
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859268-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:retatrutide: Phase 3 readout est. (NCT06859268)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in the Maintenance of Weight Reduction in Individuals With Ob
 esity\nEstimated primary completion: April 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06859268
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357415-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:retatrutide: Phase 3 readout est. (NCT07357415)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or O
 verweight\nEstimated primary completion: October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07357415
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383390-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:retatrutide: Phase 3 readout est. (NCT06383390)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: The Effect of Retatrut
 ide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults L
 iving With Obesity (TRIUMPH-Outcomes)\nEstimated primary completion: Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retatrutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 83390
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165028-118@assetmemo.bio
DTSTAMP:20261121T003113Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:retatrutide: Phase 3 readout est. (NCT07165028)
DESCRIPTION:retatrutide\, phase 3.\nStudy: A Master Protocol of Multiple Ag
 ents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disea
 se (SYNERGY-Outcomes)\nEstimated primary completion: August 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/retatrutide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07165028
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
